- 1. Department of General Surgery, Suqian People's Hospital, Nanjing Drum Tower Hospital Group of Nanjing University Medical School, Suqian 223800, Jiangsu Province, China;
- 2. Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu Province, China;
Citation: ZHUXin-qiang, GUANWen-xian. Progress of Diagnosis and Treatment of Peritoneal Metastasis from Colorectal Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(8): 1024-1028. doi: 10.7507/1007-9424.20160266 Copy
1. | Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1): 9-29. |
2. | 王锡山.从ESMO共识看结直肠癌肝转移的治疗策略.中华结直肠疾病电子杂志, 2014, 3(1): 9-11. |
3. | Ceelen WP. Current management of peritoneal carcinomatosis from colorectal cancer. Minerva Chir, 2013, 68(1): 77-86. |
4. | Koppe MJ, Boerman OC, Oyen WJ, et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg, 2006, 243(2): 212-222. |
5. | März L, Piso P. Treatment of peritoneal metastases from colorectal cancer. Gastroenterol Rep (Oxf), 2015, 3(4): 298-302. |
6. | 关雅萍, 荣学东, 张先欣, 等.肿瘤循环细胞在消化系统肿瘤中的研究进展.中华消化病与影像杂志:电子版, 2015, 5(1): 35-39. |
7. | Ghossein RA, Carusone L, Bhattacharya S. Review: polymerase chain reaction detection of micrometastases and circulating tumor cells: application to melanoma, prostate, and thyroid carcinomas. Diagn Mol Pathol, 1999, 8(4): 165-175. |
8. | Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett, 2007, 253(2): 180-204. |
9. | Wu XZ, Ma F, Wang XL. Serological diagnostic factors for liver metastasis in patients with colorectal cancer. World J Gastroenterol, 2010, 16(32): 4084-4088. |
10. | Yu H, Son GM, Joh YG. The clinical significance of preoperative serum levels of carbohydrate antigen 19-9 in colorectal cancer. J Korean Surg Soc, 2013, 84(4): 231-237. |
11. | 刘峰, 余江, 梁耀泽, 等.结直肠癌腹膜种植转移的危险因素分析.中华胃肠外科杂志, 2011, 14(4): 254-256. |
12. | Nordgard O, Oltedal S, Korner H, et al. The potential of cytokeratin 20 and mucin 2 mRNA as metastasis markers in regional lymph nodes of colon cancer patients investigated by quantitative RT-PCR. Int J Colorectal Dis, 2009, 24(3): 261-268. |
13. | 王丽娟, 王全师, 陈萍, 等. 18F-FDG PET/CT显像鉴别腹腔积液性质的价值.中华核医学与分子影像杂志, 2012, 32(2): 105-110. |
14. | Kim SJ, Kim HH, Kim YH, et al. Peritoneal metastasis: detection with 16-or 64-detector row CT in patients undergoing surgery for gastric cancer. Radiology, 2009, 253(2): 407-415. |
15. | Marin D, Catalano C, Baski M, et al. 64-section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings. Abdom Imaging, 2010, 35(6): 694-700. |
16. | Coakley FV, Choi PH, Gougoutas CA, et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology, 2002, 223(2): 495-499. |
17. | Kim TU, Kim S, Lee JW, et al. MDCT features in the differentiation of T4a gastric cancer from less-advanced gastric cancer: significance of the hyperattenuating serosa sign. Br J Radiol, 2013, 86(1029): 20130290. |
18. | Kubik-Huch RA, Dörffler W, von Schulthess GK, et al. Value of (18)F-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol, 2000, 10(5): 761-767. |
19. | Pfannenberg C, Königsrainer I, Aschoff P, et al. 18F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol, 2009, 16(5): 1295-1303. |
20. | De Gaetano AM, Calcagni ML, Rufini V, et al. Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. Abdom Imaging, 2009, 34(3): 391-402. |
21. | Turlakow A, Yeung HW, Salmon AS, et al. Peritoneal carcinoma-tosis: role of 18F-FDG PET. J Nucl Med, 2003, 44(9): 1407-1412. |
22. | De Vos N, Goethals I, Ceelen W. Clinical value of 18F-FDG-PET-CT in the preoperative staging of peritoneal carcinomatosis from colo-rectal origin. Acta Chir Belg, 2014, 114(6): 370-375. |
23. | Wang JH, Du JP, Zhang YH, et al. Dynamic changes and surveillance function of prion protein expression in gastric cancer drug resistance. World J Gastroenterol, 2011, 17(35): 3986-3993. |
24. | 梅列军, 刘俊方, 李雁, 等.应用胃肠道碘水造影对腹膜转移癌的术前评估.武汉大学学报:医学版, 2013, 34(6): 875-878. |
25. | Düx M, Richter GM, Roeren T, et al. Gastrointestinal imaging with hydrosonography and hydro-CT. Rofo, 1996, 164(5): 359-367. |
26. | Low RN. Gadolinium-enhanced MR imaging of liver capsule and peritoneum. Magn Reson Imaging Clin N Am, 2001, 9(4): 803-819, vii. |
27. | Tabrizian P, Jayakrishnan TT, Zacharias A, et al. Incorporation of diagnostic laparoscopy in the management algorithm for patients with peritoneal metastases: A multi-institutional analysis. J Surg Oncol, 2015, 111(8): 1035-1040. |
28. | Yang SH, Lin JK, Lai CR, et al. Risk factors for peritoneal dissemina-tion of colorectal cancer. J Surg Oncol, 2004, 87(4): 167-173. |
29. | van Gestel YR, Thomassen I, Lemmens VE, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol, 2014, 40(8): 963-969. |
30. | Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg, 2012, 99(5): 699-705. |
31. | Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer, 2011, 128(11): 2717-2725. |
32. | Tanaka T, Kumagai K, Shimizu K, et al. Peritoneal metastasis in gastric cancer with particular reference to lymphatic advancement; extranodal invasion is a significant risk factor for peritoneal metastasis. J Surg Oncol, 2000, 75(3): 165-171. |
33. | Yamamoto S, Akasu T, Fujita S, et al. Long-term prognostic value of conventional peritoneal cytology after curative resection for colorectal carcinoma. Jpn J Clin Oncol, 2003, 33(1): 33-37. |
34. | Bae SJ, Shin US, Ki YJ, et al. Role of peritoneal lavage cytology and prediction of prognosis and peritoneal recurrence after curative surgery for colorectal cancer. Ann Coloproctol, 2014, 30(6): 266-273. |
35. | Marutsuka T, Shimada S, Shiomori K, et al. Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis. Clin Cancer Res, 2003, 9(2): 678-685. |
36. | Rong Y, Mack P. Apoptosis induced by hyperthermia in Dunn osteosarcoma cell line in vitro. Int J Hyperthermia, 2000, 16(1): 19-27. |
37. | 彭远飞, 郑民华, 俞焙秦, 等.热CO2气腹对结肠癌细胞的增殖抑制作用及其机制.外科理论与实践, 2007, 12(5): 455-459. |
38. | Shimizu T, Murata S, Sonoda H, et al. Hyperthermic intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil in patients at high risk of peritoneal metastasis from colorectal cancer: A preliminary clinical study. Mol Clin Oncol, 2014, 2(3): 399-404. |
39. | Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer, 1999, 85(3): 529-534. |
40. | Tahara M, Ohtsu A, Boku N, et al. Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal disse-mination: a retrospective study. Gastric Cancer, 2001, 4(4): 212-218. |
41. | 金荣生, 吴旭东.进展期胃肠道癌术中腹腔温热化疗联合辅助化疗疗效观察.中国血液流变学杂志, 2005, 15(4): 620-622. |
42. | Provenzale D, Jasperson K, Ahnen DJ, et al. Colorectal Cancer Scree-ning, Version 1. 2015. J Natl Compr Canc Netw, 2015, 13(8): 959-968. |
43. | Carreres-Prieto M, Lopez-Sisamon D, Layos-Romero L. Interstitial lung disease induced by raltitrexed-oxaliplatin based chemotherapy for colorectal cancer: a case report. Farm Hosp, 2015, 39(2): 118-119. |
44. | Noura S, Ohue M, Seki Y, et al. Long-term prognostic value of conventional peritoneal lavage cytology in patients undergoing curative colorectal cancer resection. Dis Colon Rectum, 2009, 52(7): 1312-1320. |
45. | Turner N, Tran B, Tran PV, et al. Primary tumor resection in pati-ents with metastatic colorectal cancer is associated with reversal of systemic inflammation and improved survival. Clin Colorectal Cancer, 2015, 14(3): 185-191. |
46. | Furuhata T, Okita K, Nishidate T, et al. Oncological benefit of primary tumor resection with high tie lymph node dissection in unresectable colorectal cancer with synchronous peritoneal metas-tasis: a propensity score analysis of data from a multi-institute database. Int J Clin Oncol, 2015, 20(5): 922-927. |
47. | Sato H, Toyama K, Koide Y, et al. Prognoses and treatment strate-gies for synchronous peritoneal dissemination of colorectal carci-noma. Surg Today, 2015 Oct 3. [Epub ahead of print]. |
48. | Hatano S, Matsuzawa T, Chika N, et al. Is PCI effective in predicting prognosis in the era of oxaliplatin-based chemotherapy in stage Ⅳ colorectal cancer with peritoneal dissemination? Gan To Kagaku Ryoho, 2014, 41(12): 1692-1694. |
49. | Ozawa H, Kotake K, Kobayashi H, et al. Prognostic factors for peritoneal carcinomatosis originating from colorectal cancer: an analysis of 921 patients from a multi-institutional database. Surg Today, 2014, 44(9): 1643-1650. |
50. | Stillwell AP, Ho YH, Veitch C. Systematic review of prognostic factors related to overall survival in patients with stage Ⅳ colorectal cancer and unresectable metastases. World J Surg, 2011, 35(3): 684-692. |
51. | Cloutier AS, Faron M, Honore C, et al. Second-look surgery plus HIPEC for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Should we resect the initial anastomosis? An observational study. Eur J Surg Oncol, 2015, 41(8): 1068-1073. |
52. | Kim IY, Kim BR, Kim HS, et al. Differences in clinical features between laparoscopy and open resection for primary tumor in patients with stage Ⅳ colorectal cancer. Onco Targets Ther, 2015, 8: 3441-3448. |
53. | Kobayashi H, Kotake K, Sugihara K. Impact of adjuvant chemo-therapy in patients with curatively resected stage Ⅳ colorectal cancer.Medicine (Baltimore), 2015, 94(17): e696. |
54. | 薛雾松, 门斯烨, 张少辉, 等.结直肠癌转移灶的综合治疗.中国普外基础与临床杂志, 2012, 19(8): 894-898. |
55. | Tomita R, Fujisaki S, Sakurai K, et al. Malignant small bowel ileus due to recurrent colorectal cancer with peritoneal metastasis. Gan To Kagaku Ryoho, 2014, 41(12): 1689-1691. |
56. | Chan CH, Cusack JC, Ryan DP. A critical look at local-regional management of peritoneal metastasis. Hematol Oncol Clin North Am, 2015, 29(1): 153-158. |
57. | Mirnezami R, Mehta AM, Chandrakumaran K, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemo-therapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer, 2014, 111(8): 1500-1508. |
58. | Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy:retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol, 2010, 28(1): 63-68. |
59. | Shen P, Thai K, Stewart JH, et al. Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol, 2008, 15(12): 3422-3432. |
60. | Demtröder C, Solass W, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis, 2016, 18(4): 364-371. |
61. | Odendahl K, Solass W, Demtröder C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Eur J Surg Oncol, 2015, 41(10): 1379-1385. |
62. | Aoyagi T, Terracina KP, Raza A, et al. Current treatment options for colon cancer peritoneal carcinomatosis. World J Gastroenterol, 2014, 20(35): 12493-12500. |
- 1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1): 9-29.
- 2. 王锡山.从ESMO共识看结直肠癌肝转移的治疗策略.中华结直肠疾病电子杂志, 2014, 3(1): 9-11.
- 3. Ceelen WP. Current management of peritoneal carcinomatosis from colorectal cancer. Minerva Chir, 2013, 68(1): 77-86.
- 4. Koppe MJ, Boerman OC, Oyen WJ, et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg, 2006, 243(2): 212-222.
- 5. März L, Piso P. Treatment of peritoneal metastases from colorectal cancer. Gastroenterol Rep (Oxf), 2015, 3(4): 298-302.
- 6. 关雅萍, 荣学东, 张先欣, 等.肿瘤循环细胞在消化系统肿瘤中的研究进展.中华消化病与影像杂志:电子版, 2015, 5(1): 35-39.
- 7. Ghossein RA, Carusone L, Bhattacharya S. Review: polymerase chain reaction detection of micrometastases and circulating tumor cells: application to melanoma, prostate, and thyroid carcinomas. Diagn Mol Pathol, 1999, 8(4): 165-175.
- 8. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett, 2007, 253(2): 180-204.
- 9. Wu XZ, Ma F, Wang XL. Serological diagnostic factors for liver metastasis in patients with colorectal cancer. World J Gastroenterol, 2010, 16(32): 4084-4088.
- 10. Yu H, Son GM, Joh YG. The clinical significance of preoperative serum levels of carbohydrate antigen 19-9 in colorectal cancer. J Korean Surg Soc, 2013, 84(4): 231-237.
- 11. 刘峰, 余江, 梁耀泽, 等.结直肠癌腹膜种植转移的危险因素分析.中华胃肠外科杂志, 2011, 14(4): 254-256.
- 12. Nordgard O, Oltedal S, Korner H, et al. The potential of cytokeratin 20 and mucin 2 mRNA as metastasis markers in regional lymph nodes of colon cancer patients investigated by quantitative RT-PCR. Int J Colorectal Dis, 2009, 24(3): 261-268.
- 13. 王丽娟, 王全师, 陈萍, 等. 18F-FDG PET/CT显像鉴别腹腔积液性质的价值.中华核医学与分子影像杂志, 2012, 32(2): 105-110.
- 14. Kim SJ, Kim HH, Kim YH, et al. Peritoneal metastasis: detection with 16-or 64-detector row CT in patients undergoing surgery for gastric cancer. Radiology, 2009, 253(2): 407-415.
- 15. Marin D, Catalano C, Baski M, et al. 64-section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings. Abdom Imaging, 2010, 35(6): 694-700.
- 16. Coakley FV, Choi PH, Gougoutas CA, et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology, 2002, 223(2): 495-499.
- 17. Kim TU, Kim S, Lee JW, et al. MDCT features in the differentiation of T4a gastric cancer from less-advanced gastric cancer: significance of the hyperattenuating serosa sign. Br J Radiol, 2013, 86(1029): 20130290.
- 18. Kubik-Huch RA, Dörffler W, von Schulthess GK, et al. Value of (18)F-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol, 2000, 10(5): 761-767.
- 19. Pfannenberg C, Königsrainer I, Aschoff P, et al. 18F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol, 2009, 16(5): 1295-1303.
- 20. De Gaetano AM, Calcagni ML, Rufini V, et al. Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. Abdom Imaging, 2009, 34(3): 391-402.
- 21. Turlakow A, Yeung HW, Salmon AS, et al. Peritoneal carcinoma-tosis: role of 18F-FDG PET. J Nucl Med, 2003, 44(9): 1407-1412.
- 22. De Vos N, Goethals I, Ceelen W. Clinical value of 18F-FDG-PET-CT in the preoperative staging of peritoneal carcinomatosis from colo-rectal origin. Acta Chir Belg, 2014, 114(6): 370-375.
- 23. Wang JH, Du JP, Zhang YH, et al. Dynamic changes and surveillance function of prion protein expression in gastric cancer drug resistance. World J Gastroenterol, 2011, 17(35): 3986-3993.
- 24. 梅列军, 刘俊方, 李雁, 等.应用胃肠道碘水造影对腹膜转移癌的术前评估.武汉大学学报:医学版, 2013, 34(6): 875-878.
- 25. Düx M, Richter GM, Roeren T, et al. Gastrointestinal imaging with hydrosonography and hydro-CT. Rofo, 1996, 164(5): 359-367.
- 26. Low RN. Gadolinium-enhanced MR imaging of liver capsule and peritoneum. Magn Reson Imaging Clin N Am, 2001, 9(4): 803-819, vii.
- 27. Tabrizian P, Jayakrishnan TT, Zacharias A, et al. Incorporation of diagnostic laparoscopy in the management algorithm for patients with peritoneal metastases: A multi-institutional analysis. J Surg Oncol, 2015, 111(8): 1035-1040.
- 28. Yang SH, Lin JK, Lai CR, et al. Risk factors for peritoneal dissemina-tion of colorectal cancer. J Surg Oncol, 2004, 87(4): 167-173.
- 29. van Gestel YR, Thomassen I, Lemmens VE, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol, 2014, 40(8): 963-969.
- 30. Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg, 2012, 99(5): 699-705.
- 31. Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer, 2011, 128(11): 2717-2725.
- 32. Tanaka T, Kumagai K, Shimizu K, et al. Peritoneal metastasis in gastric cancer with particular reference to lymphatic advancement; extranodal invasion is a significant risk factor for peritoneal metastasis. J Surg Oncol, 2000, 75(3): 165-171.
- 33. Yamamoto S, Akasu T, Fujita S, et al. Long-term prognostic value of conventional peritoneal cytology after curative resection for colorectal carcinoma. Jpn J Clin Oncol, 2003, 33(1): 33-37.
- 34. Bae SJ, Shin US, Ki YJ, et al. Role of peritoneal lavage cytology and prediction of prognosis and peritoneal recurrence after curative surgery for colorectal cancer. Ann Coloproctol, 2014, 30(6): 266-273.
- 35. Marutsuka T, Shimada S, Shiomori K, et al. Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis. Clin Cancer Res, 2003, 9(2): 678-685.
- 36. Rong Y, Mack P. Apoptosis induced by hyperthermia in Dunn osteosarcoma cell line in vitro. Int J Hyperthermia, 2000, 16(1): 19-27.
- 37. 彭远飞, 郑民华, 俞焙秦, 等.热CO2气腹对结肠癌细胞的增殖抑制作用及其机制.外科理论与实践, 2007, 12(5): 455-459.
- 38. Shimizu T, Murata S, Sonoda H, et al. Hyperthermic intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil in patients at high risk of peritoneal metastasis from colorectal cancer: A preliminary clinical study. Mol Clin Oncol, 2014, 2(3): 399-404.
- 39. Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer, 1999, 85(3): 529-534.
- 40. Tahara M, Ohtsu A, Boku N, et al. Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal disse-mination: a retrospective study. Gastric Cancer, 2001, 4(4): 212-218.
- 41. 金荣生, 吴旭东.进展期胃肠道癌术中腹腔温热化疗联合辅助化疗疗效观察.中国血液流变学杂志, 2005, 15(4): 620-622.
- 42. Provenzale D, Jasperson K, Ahnen DJ, et al. Colorectal Cancer Scree-ning, Version 1. 2015. J Natl Compr Canc Netw, 2015, 13(8): 959-968.
- 43. Carreres-Prieto M, Lopez-Sisamon D, Layos-Romero L. Interstitial lung disease induced by raltitrexed-oxaliplatin based chemotherapy for colorectal cancer: a case report. Farm Hosp, 2015, 39(2): 118-119.
- 44. Noura S, Ohue M, Seki Y, et al. Long-term prognostic value of conventional peritoneal lavage cytology in patients undergoing curative colorectal cancer resection. Dis Colon Rectum, 2009, 52(7): 1312-1320.
- 45. Turner N, Tran B, Tran PV, et al. Primary tumor resection in pati-ents with metastatic colorectal cancer is associated with reversal of systemic inflammation and improved survival. Clin Colorectal Cancer, 2015, 14(3): 185-191.
- 46. Furuhata T, Okita K, Nishidate T, et al. Oncological benefit of primary tumor resection with high tie lymph node dissection in unresectable colorectal cancer with synchronous peritoneal metas-tasis: a propensity score analysis of data from a multi-institute database. Int J Clin Oncol, 2015, 20(5): 922-927.
- 47. Sato H, Toyama K, Koide Y, et al. Prognoses and treatment strate-gies for synchronous peritoneal dissemination of colorectal carci-noma. Surg Today, 2015 Oct 3. [Epub ahead of print].
- 48. Hatano S, Matsuzawa T, Chika N, et al. Is PCI effective in predicting prognosis in the era of oxaliplatin-based chemotherapy in stage Ⅳ colorectal cancer with peritoneal dissemination? Gan To Kagaku Ryoho, 2014, 41(12): 1692-1694.
- 49. Ozawa H, Kotake K, Kobayashi H, et al. Prognostic factors for peritoneal carcinomatosis originating from colorectal cancer: an analysis of 921 patients from a multi-institutional database. Surg Today, 2014, 44(9): 1643-1650.
- 50. Stillwell AP, Ho YH, Veitch C. Systematic review of prognostic factors related to overall survival in patients with stage Ⅳ colorectal cancer and unresectable metastases. World J Surg, 2011, 35(3): 684-692.
- 51. Cloutier AS, Faron M, Honore C, et al. Second-look surgery plus HIPEC for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Should we resect the initial anastomosis? An observational study. Eur J Surg Oncol, 2015, 41(8): 1068-1073.
- 52. Kim IY, Kim BR, Kim HS, et al. Differences in clinical features between laparoscopy and open resection for primary tumor in patients with stage Ⅳ colorectal cancer. Onco Targets Ther, 2015, 8: 3441-3448.
- 53. Kobayashi H, Kotake K, Sugihara K. Impact of adjuvant chemo-therapy in patients with curatively resected stage Ⅳ colorectal cancer.Medicine (Baltimore), 2015, 94(17): e696.
- 54. 薛雾松, 门斯烨, 张少辉, 等.结直肠癌转移灶的综合治疗.中国普外基础与临床杂志, 2012, 19(8): 894-898.
- 55. Tomita R, Fujisaki S, Sakurai K, et al. Malignant small bowel ileus due to recurrent colorectal cancer with peritoneal metastasis. Gan To Kagaku Ryoho, 2014, 41(12): 1689-1691.
- 56. Chan CH, Cusack JC, Ryan DP. A critical look at local-regional management of peritoneal metastasis. Hematol Oncol Clin North Am, 2015, 29(1): 153-158.
- 57. Mirnezami R, Mehta AM, Chandrakumaran K, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemo-therapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer, 2014, 111(8): 1500-1508.
- 58. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy:retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol, 2010, 28(1): 63-68.
- 59. Shen P, Thai K, Stewart JH, et al. Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol, 2008, 15(12): 3422-3432.
- 60. Demtröder C, Solass W, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis, 2016, 18(4): 364-371.
- 61. Odendahl K, Solass W, Demtröder C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Eur J Surg Oncol, 2015, 41(10): 1379-1385.
- 62. Aoyagi T, Terracina KP, Raza A, et al. Current treatment options for colon cancer peritoneal carcinomatosis. World J Gastroenterol, 2014, 20(35): 12493-12500.